

# Alexander C J Van Akkooi

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3957807/publications.pdf>

Version: 2024-02-01

162  
papers

8,605  
citations

117625

34  
h-index

48315

88  
g-index

165  
all docs

165  
docs citations

165  
times ranked

9384  
citing authors

#	ARTICLE	IF	CITATIONS
1	Talimogene Laherparepvec (T-VEC) for the Treatment of Advanced Locoregional Melanoma After Failure of Immunotherapy: An International Multi-Institutional Experience. <i>Annals of Surgical Oncology</i> , 2022, 29, 791-801.	1.5	18
2	External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort. <i>Annals of Surgical Oncology</i> , 2022, 29, 1637-1644.	1.5	5
3	ASO Visual Abstract: External Validation of a Dutch Predictive Nomogram for Complete Response to T-VEC in an Independent American Patient Cohort. <i>Annals of Surgical Oncology</i> , 2022, 29, 1647.	1.5	0
4	OUP accepted manuscript. <i>British Journal of Surgery</i> , 2022, , .	0.3	0
5	Neoadjuvant Systemic Therapy (NAST) in Patients with Melanoma: Surgical Considerations by the International Neoadjuvant Melanoma Consortium (INMC). <i>Annals of Surgical Oncology</i> , 2022, 29, 3694-3708.	1.5	21
6	ASO Author Reflections: Validation of Prediction Model for Response to Treatment with T-VEC. <i>Annals of Surgical Oncology</i> , 2022, 29, 1645-1646.	1.5	0
7	Isolated limb perfusion for locally advanced melanoma in the immunotherapy era. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1288-1292.	1.0	4
8	Neoadjuvant Immune Checkpoint Inhibitor Therapy in Melanoma: Efficacy, Safety and Timing. <i>BioDrugs</i> , 2022, 36, 373-380.	4.6	2
9	18F-FDG PET/CT During Neoadjuvant Targeted Therapy in Prior Unresectable Stage III Melanoma Patients. <i>Clinical Nuclear Medicine</i> , 2022, 47, 583-589.	1.3	4
10	European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics: Update 2022. <i>European Journal of Cancer</i> , 2022, 170, 236-255.	2.8	102
11	Single agent Talimogene Laherparepvec for stage IIIB-IVM1c melanoma patients: A systematic review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2022, 175, 103705.	4.4	3
12	Re-introduction of T-VEC Monotherapy in Recurrent Melanoma is Effective. <i>Journal of Immunotherapy</i> , 2022, Publish Ahead of Print, .	2.4	1
13	Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline " Update 2022. <i>European Journal of Cancer</i> , 2022, 171, 203-231.	2.8	51
14	The Clinical Utility of Neuron-Specific Enolase (NSE) Serum Levels as a Biomarker for Merkel Cell Carcinoma (MCC). <i>Annals of Surgical Oncology</i> , 2021, 28, 1019-1028.	1.5	20
15	T-VEC for stage IIIB-IVM1a melanoma achieves high rates of complete and durable responses and is associated with tumor load: a clinical prediction model. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 2291-2300.	4.2	16
16	The efficacy of immunotherapy for in-transit metastases of melanoma: an analysis of randomized controlled trials. <i>Melanoma Research</i> , 2021, 31, 181-185.	1.2	14
17	Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). <i>Nature Medicine</i> , 2021, 27, 301-309.	30.7	218
18	Neoadjuvant Cytoreductive Treatment With BRAF/MEK Inhibition of Prior Unresectable Regionally Advanced Melanoma to Allow Complete Surgical Resection, REDUCTOR. <i>Annals of Surgery</i> , 2021, 274, 383-389.	4.2	28

#	ARTICLE	IF	CITATIONS
19	The prognostic value of the interferon-gamma (IFN $\gamma$ ) signature in patients with macroscopic stage III melanoma treated with and without adjuvant systemic therapy.. Journal of Clinical Oncology, 2021, 39, 9579-9579.	1.6	5
20	Postoperative radiotherapy in Merkel cell carcinoma (MCC).. Journal of Clinical Oncology, 2021, 39, 9575-9575.	1.6	0
21	Is adjuvant treatment for melanoma in clinical practice comparable to trials? The first population-based results.. Journal of Clinical Oncology, 2021, 39, e21523-e21523.	1.6	0
22	The value of lymph node ultrasound and whole body 18F-FDG PET/CT in stage IIB/C melanoma patients prior to SLNB. European Journal of Surgical Oncology, 2021, 47, 1157-1162.	1.0	6
23	External validation of a Dutch predictive nomogram for complete response to T-VEC in an independent American patient cohort.. Journal of Clinical Oncology, 2021, 39, 9563-9563.	1.6	0
24	A phase II, open-label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel cell carcinoma progressing on anti-PD-(L)1 antibody therapy: The MERKLIN 2 study.. Journal of Clinical Oncology, 2021, 39, TPS9592-TPS9592.	1.6	2
25	False positive FDG uptake in melanoma patients treated with talimogene laherparepvec (T-VEC). Journal of Surgical Oncology, 2021, 124, 1161-1165.	1.7	1
26	Adjuvant treatment for melanoma in clinical practice – Trial versus reality. European Journal of Cancer, 2021, 158, 234-245.	2.8	12
27	A Retrospective Chart Review Study of Real-World Use of Talimogene Laherparepvec in Unresectable Stage III Melanoma in Four European Countries. Advances in Therapy, 2021, 38, 1245-1262.	2.9	12
28	Trends in survival and costs in metastatic melanoma in the era of novel targeted and immunotherapeutic drugs. ESMO Open, 2021, 6, 100320.	4.5	10
29	Treatment of melanoma of unknown primary in the era of immunotherapy and targeted therapy: A Dutch population-based study. International Journal of Cancer, 2020, 146, 26-34.	5.1	28
30	External validation of the American Joint Committee on Cancer 8th edition melanoma staging system: who needs adjuvant treatment?. Melanoma Research, 2020, 30, 185-192.	1.2	17
31	Adjuvant Therapy for Melanoma: Past, Current, and Future Developments. Cancers, 2020, 12, 1994.	3.7	26
32	The use of FDG-PET/CT to detect early recurrence after resection of high-risk stage III melanoma. Journal of Surgical Oncology, 2020, 122, 1328-1336.	1.7	4
33	Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial. Journal of Clinical Oncology, 2020, 38, 3925-3936.	1.6	192
34	Surgery for Unresectable Stage III C and IV Melanoma in the Era of New Systemic Therapy. Cancers, 2020, 12, 1176.	3.7	11
35	ASO Author Reflections: The Landmark Series: Neoadjuvant Systemic Therapy (NAST) for Stage 3 Melanoma Patients: A Potential Paradigm Shift in Management. Annals of Surgical Oncology, 2020, 27, 2201-2202.	1.5	0
36	ASO Author Reflections: Neuron-Specific Enolase as a Valuable Biomarker for Patients with Merkel Cell Carcinoma in the Era of Immunotherapy. Annals of Surgical Oncology, 2020, 27, 769-770.	1.5	0

#	ARTICLE	IF	CITATIONS
37	Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: Results of the European Organisation for Research and Treatment of Cancer 18081 randomised trial. <i>European Journal of Cancer</i> , 2020, 133, 94-103.	2.8	13
38	The EORTC-DeCOG nomogram adequately predicts outcomes of patients with sentinel node-â€œpositive melanoma without the need for completion lymph node dissection. <i>European Journal of Cancer</i> , 2020, 134, 9-18.	2.8	11
39	Challenges in sentinel node pathology in the era of adjuvant treatment. <i>Journal of Surgical Oncology</i> , 2020, 122, 964-972.	1.7	7
40	Broadening indications for neoadjuvant immunotherapy. <i>British Journal of Dermatology</i> , 2020, 183, 421-422.	1.5	1
41	Healthcare Costs of Metastatic Cutaneous Melanoma in the Era of Immunotherapeutic and Targeted Drugs. <i>Cancers</i> , 2020, 12, 1003.	3.7	15
42	Complete response to talimogene laherparepvec in a primary acral lentiginous melanoma. <i>Melanoma Research</i> , 2020, 30, 548-551.	1.2	4
43	Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10000-10000.	1.6	21
44	First safety and efficacy results of PRADO: A phase II study of personalized response-driven surgery and adjuvant therapy after neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in resectable stage III melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10002-10002.	1.6	57
45	Twenty-four months RFS and updated toxicity data from OpACIN-neo: A study to identify the optimal dosing schedule of neoadjuvant ipilimumab (IPI) and nivolumab (NIVO) in stage III melanoma.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10015-10015.	1.6	18
46	Checkpoint inhibitor treatment in patients with isolated in-transit melanoma metastases.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10070-10070.	1.6	5
47	The use of PET/CT to detect early recurrence after resection of high-risk stage III melanoma, prior to the start of adjuvant therapy and during follow-up.. <i>Journal of Clinical Oncology</i> , 2020, 38, e22039-e22039.	1.6	1
48	Personalized combination of neoadjuvant domatinostat, nivolumab and ipilimumab in macroscopic stage III melanoma patients stratified according to the interferon-gamma signature: The DONIMI study.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS10087-TPS10087.	1.6	9
49	The value of lymph node ultrasound and whole body PET/CT in stage IIB/C patients prior to SLNB.. <i>Journal of Clinical Oncology</i> , 2020, 38, e22079-e22079.	1.6	0
50	Rate of complete and durable responses of intralesional therapy with talimogene laherparepvec for stage IIIB-IVM1a melanoma and association with tumor load.. <i>Journal of Clinical Oncology</i> , 2020, 38, e22089-e22089.	1.6	0
51	Health-related quality of life in stage III melanoma patients treated with neoadjuvant ipilimumab and nivolumab followed by index lymph node excision only, compared to therapeutic lymph node dissection: First results of the PRADO trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10064-10064.	1.6	0
52	Surgery for unresectable stage IIIC and IV melanoma in the era of new systemic therapy.. <i>Journal of Clinical Oncology</i> , 2020, 38, 10032-10032.	1.6	0
53	Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. <i>Lancet Oncology</i> , The, 2019, 20, e378-e389.	10.7	155
54	Surgery for Metastatic Melanoma: an Evolving Concept. <i>Current Oncology Reports</i> , 2019, 21, 98.	4.0	11

#	ARTICLE	IF	CITATIONS
55	A systematic review and meta-analysis of locoregional treatments for in-transit melanoma. <i>Journal of Surgical Oncology</i> , 2019, 120, 1056-1057.	1.7	1
56	Treatment and survival of Merkel cell carcinoma since 1993: A population-based cohort study in The Netherlands. <i>Journal of the American Academy of Dermatology</i> , 2019, 81, 977-983.	1.2	8
57	Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , 2019, 30, 1884-1901.	1.2	394
58	High response rates for T-VEC in early metastatic melanoma (stage IIIB/C-IVM1a). <i>International Journal of Cancer</i> , 2019, 145, 974-978.	5.1	67
59	Outcome after surgical treatment of dermatofibrosarcoma protuberans: Is clinical follow-up always indicated?. <i>Cancer</i> , 2019, 125, 735-741.	4.1	33
60	Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. <i>Lancet Oncology</i> , The, 2019, 20, 948-960.	10.7	346
61	An updated European Organisation for Research and Treatment of Cancer (EORTC) protocol for pathological evaluation of sentinel lymph nodes for melanoma. <i>European Journal of Cancer</i> , 2019, 114, 1-7.	2.8	38
62	Reply to: Letter re: Efficacy of isolated limb perfusion (ILP) in patients with Merkel cell carcinoma: A multicenter experience. <i>European Journal of Surgical Oncology</i> , 2019, 45, 1122-1123.	1.0	0
63	The extent of surgery for stage III melanoma: how much is appropriate?. <i>Lancet Oncology</i> , The, 2019, 20, e167-e174.	10.7	27
64	Parotidectomy in patients with head and neck cutaneous melanoma with cervical lymph node involvement. <i>Head and Neck</i> , 2019, 41, 2264-2270.	2.0	6
65	Primary Melanoma: from History to Actual Debates. <i>Current Oncology Reports</i> , 2019, 21, 112.	4.0	8
66	Adjuvant systemic therapy in high-risk melanoma. <i>Melanoma Research</i> , 2019, 29, 358-364.	1.2	16
67	Dysfunctional CD8 T Cells Form a Proliferative, Dynamically Regulated Compartment within Human Melanoma. <i>Cell</i> , 2019, 176, 775-789.e18.	28.9	760
68	Recent developments in lymph node surgery for melanoma. <i>British Journal of Dermatology</i> , 2019, 180, 5-7.	1.5	5
69	Time dependent dynamics of wound complications after preoperative radiotherapy in Extremity Soft Tissue Sarcomas. <i>European Journal of Surgical Oncology</i> , 2019, 45, 684-690.	1.0	23
70	Validation of a Nomogram for Non-sentinel Node Positivity in Melanoma Patients, and Its Clinical Implications: A Brazilian-Dutch Study. <i>Annals of Surgical Oncology</i> , 2019, 26, 395-405.	1.5	16
71	Personalized response-driven adjuvant therapy after combination ipilimumab and nivolumab in high-risk resectable stage III melanoma: PRADO trial.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9605-TPS9605.	1.6	16
72	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018, 378, 1789-1801.	27.0	1,441

#	ARTICLE	IF	CITATIONS
73	Real-world healthcare costs of ipilimumab in patients with advanced cutaneous melanoma in The Netherlands. <i>Anti-Cancer Drugs</i> , 2018, 29, 579-588.	1.4	11
74	Risk stratification of sentinel node–positive melanoma patients defines surgical management and adjuvant therapy treatment considerations. <i>European Journal of Cancer</i> , 2018, 96, 25-33.	2.8	59
75	Real-world use, safety, and survival of ipilimumab in metastatic cutaneous melanoma in The Netherlands. <i>Anti-Cancer Drugs</i> , 2018, 29, 572-578.	1.4	11
76	Lymph node ratio as a prognostic factor in melanoma: results from European Organization for Research and Treatment of Cancer 18871, 18952, and 18991 studies. <i>Melanoma Research</i> , 2018, 28, 222-229.	1.2	5
77	Gamma probe and ultrasound-guided fine needle aspiration cytology of the sentinel node (GULF) trial. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2018, 45, 1926-1933.	6.4	5
78	Improved stratification of pT1 melanoma according to the 8th American Joint Committee on Cancer staging edition criteria: A Dutch population-based study. <i>European Journal of Cancer</i> , 2018, 92, 100-107.	2.8	8
79	Eighth American Joint Committee on Cancer (AJCC) melanoma classification: Let us reconsider stage III. <i>European Journal of Cancer</i> , 2018, 91, 168-170.	2.8	33
80	Positron emission tomography/computed tomography evaluation of oncolytic virus therapy efficacy in melanoma. <i>European Journal of Cancer</i> , 2018, 90, 149-152.	2.8	4
81	Surgical and Anatomic Considerations of Malignancies Affecting the Groin: Consideration for Melanoma. , 2018, , 63-74.		0
82	Practice-Changing Developments in Stage III Melanoma: Surgery, Adjuvant Targeted Therapy, and Immunotherapy. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2018, 38, 759-762.	3.8	13
83	Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma. <i>Nature Medicine</i> , 2018, 24, 1655-1661.	30.7	599
84	Melanoma. <i>Lancet</i> , The, 2018, 392, 971-984.	13.7	1,016
85	Merkel cell carcinoma: Clinical outcome and prognostic factors in 351 patients. <i>Journal of Surgical Oncology</i> , 2018, 117, 1768-1775.	1.7	36
86	Vemurafenib in BRAF-mutant metastatic melanoma patients in real-world clinical practice: prognostic factors associated with clinical outcomes. <i>Melanoma Research</i> , 2018, 28, 326-332.	1.2	8
87	Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma. <i>Annals of Oncology</i> , 2018, 29, 1861-1868.	1.2	135
88	External validation of the 8th Edition Melanoma Staging System of the American Joint Committee on Cancer (AJCC): Effect of adding EORTC sentinel node (SN) tumor burden criteria on prognostic accuracy in stage III.. <i>Journal of Clinical Oncology</i> , 2018, 36, 9500-9500.	1.6	8
89	Implementation of the 7th edition <sc>AJCC</sc> staging system: Effects on staging and survival for pT1 melanoma. A Dutch population based study. <i>International Journal of Cancer</i> , 2017, 140, 1802-1808.	5.1	10
90	Isolated Limb Perfusion for Melanoma is Safe and Effective in Elderly Patients. <i>Annals of Surgical Oncology</i> , 2017, 24, 1997-2005.	1.5	29

#	ARTICLE	IF	CITATIONS
91	Long-term results of ultrasound guided fine needle aspiration cytology in conjunction with sentinel node biopsy support step-wise approach in melanoma. <i>European Journal of Surgical Oncology</i> , 2017, 43, 1509-1516.	1.0	13
92	Clinical prognostic markers in stage IIIC melanoma. <i>Journal of Surgical Oncology</i> , 2017, 116, 244-251.	1.7	7
93	PET/CT surveillance detects asymptomatic recurrences in stage IIIB and IIIC melanoma patients: a prospective cohort study. <i>Melanoma Research</i> , 2017, 27, 251-257.	1.2	16
94	Gamma probe and ultrasound guided fine needle aspiration cytology of the sentinel node (GULF) trial - overview of the literature, pilot and study protocol. <i>BMC Cancer</i> , 2017, 17, 258.	2.6	5
95	Immediate completion lymph node dissection in stage IIIA melanoma does not provide significant additional staging information beyond EORTC SN tumour burden criteria. <i>European Journal of Cancer</i> , 2017, 87, 212-215.	2.8	22
96	Concurrent Merkel Cell Carcinoma and Melanoma in Individual Patients Presents a Treatment Challenge: A Case Series. <i>Clinical Skin Cancer</i> , 2017, 2, 69-72.	0.1	1
97	Efficacy of isolated limb perfusion (ILP) in patients with Merkel cell carcinoma (MCC): A multicenter experience. <i>European Journal of Surgical Oncology</i> , 2017, 43, 2157-2162.	1.0	12
98	Isolated limb perfusion for locally advanced angiosarcoma in extremities: A multi-centre study. <i>European Journal of Cancer</i> , 2017, 85, 114-121.	2.8	12
99	Prevention of Seroma After Inguinal Lymph Node Dissection by TachoSil Application: A Pilot Study. <i>Clinical Skin Cancer</i> , 2017, 2, 5-9.	0.1	0
100	Pre-SN Ultrasound-FNAC can be Sensitive for Lymph Node Metastases in Melanoma Patients if Performed with the Use of the Berlin Criteria. <i>Annals of Surgical Oncology</i> , 2017, 24, 661-662.	1.5	7
101	Comment: Detailed Pathologic Examination of Completion Node Dissection Specimens and Outcome for Melanoma Patients with Minimal (<math>\leq 1\text{mm}</math>) Sentinel Lymph Node Metastases. <i>Annals of Surgical Oncology</i> , 2017, 24, 658-659.	1.5	0
102	Reply to "Current controversies on sentinel node biopsy in thin and thick cutaneous melanoma". <i>European Journal of Surgical Oncology</i> , 2017, 43, 508.	1.0	1
103	Sentinel node biopsy in melanoma: Current controversies addressed. <i>European Journal of Surgical Oncology</i> , 2017, 43, 517-533.	1.0	52
104	Neoadjuvant ipilimumab + nivolumab (IPI+NIVO) in palpable stage III melanoma: Updated data from the OpACIN trial and first immunological analyses.. <i>Journal of Clinical Oncology</i> , 2017, 35, 9586-9586.	1.6	23
105	Multicenter phase 2 study to identify the optimal neo-adjuvant combination scheme of ipilimumab (IPI) and nivolumab (NIVO) (OpACIN-neo).. <i>Journal of Clinical Oncology</i> , 2017, 35, TPS9600-TPS9600.	1.6	4
106	Efficacy and safety of isolated limb perfusion for melanoma in elderly patients.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21549-e21549.	1.6	0
107	The interval between primary melanoma excision and sentinel node biopsy is not associated with survival in sentinel node positive patients " An EORTC Melanoma Group study. <i>European Journal of Surgical Oncology</i> , 2016, 42, 1906-1913.	1.0	25
108	Neoadjuvant Cytoreductive Treatment of Regionally Advanced Melanoma With BRAF/MEK Inhibition: Study Protocol of the REDUCTOR (Cytoreductive Treatment of Dabrafenib Combined With Trametinib) Tj ETQq0 0 0 r gBT /Overlock 10 T	0.1	6

#	ARTICLE	IF	CITATIONS
109	Unknown Primary Melanoma: Worldwide Survey on Clinical Management. <i>Dermatology</i> , 2016, 232, 704-707.	2.1	20
110	(Near-Infrared) Fluorescence-Guided Surgery Under Ambient Light Conditions: A Next Step to Embedment of the Technology in Clinical Routine. <i>Annals of Surgical Oncology</i> , 2016, 23, 2586-2595.	1.5	45
111	Response to Wheatley et al., "Surgical excision margins in primary cutaneous melanoma: A meta-analysis and Bayesian probability evaluation"; <i>Cancer Treatment Reviews</i> . <i>Cancer Treatment Reviews</i> , 2016, 45, 76.	7.7	5
112	The Diagnostic Value of PET/CT Imaging in Melanoma Groin Metastases. <i>Annals of Surgical Oncology</i> , 2016, 23, 2323-2329.	1.5	5
113	Effects of time interval between primary melanoma excision and sentinel node biopsy on positivity rate and survival. <i>European Journal of Cancer</i> , 2016, 67, 164-173.	2.8	30
114	Clinical Prognostic Markers in Stage IIIB Melanoma. <i>Annals of Surgical Oncology</i> , 2016, 23, 4195-4202.	1.5	4
115	News From the Society of Surgical Oncology (SSO) Annual Cancer Symposium (March 15-18, 2017) <i>Tj ETQq1 1 0.784314 rgBT /Over</i> <i>Clinical Skin Cancer</i> , 2016, 1, 57-58.	0.1	0
116	Blue dye can be safely omitted in most sentinel node procedures for melanoma. <i>Melanoma Research</i> , 2016, 26, 464-468.	1.2	20
117	Ultrasound of the sentinel node in melanoma patients: echo-free island is a discriminatory morphologic feature for node positivity. <i>Melanoma Research</i> , 2016, 26, 267-271.	1.2	16
118	Surgical Management and Adjuvant Therapy for High-Risk and Metastatic Melanoma. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2016, 36, e505-e514.	3.8	17
119	Making Peace With Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 4227-4228.	1.6	0
120	Ultrasound diagnosis of an atypical axillary lesion. <i>Melanoma Research</i> , 2014, 24, 517-521.	1.2	0
121	Sentinel node followed by completion lymph node dissection versus nodal observation. <i>Melanoma Research</i> , 2014, 24, 291-294.	1.2	25
122	Pigmentation in the sentinel node correlates with increased sentinel node tumor burden in melanoma patients. <i>Melanoma Research</i> , 2014, 24, 261-266.	1.2	6
123	SLNB in melanoma "DFS a true and cost-effective benefit?. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 680-680.	27.6	0
124	Ultrasound-guided fine needle aspiration cytology as an addendum to sentinel lymph node biopsy can perfect the staging strategy in melanoma patients. <i>European Journal of Cancer</i> , 2014, 50, 2280-2288.	2.8	47
125	The prognostic significance of sentinel node tumour burden in melanoma patients: An international, multicenter study of 1539 sentinel node-positive melanoma patients. <i>European Journal of Cancer</i> , 2014, 50, 111-120.	2.8	127
126	Conditional survival of malignant melanoma in The Netherlands: 1994-2008. <i>European Journal of Cancer</i> , 2014, 50, 602-610.	2.8	21



#	ARTICLE	IF	CITATIONS
127	MSLT-1 is a biomarker, not a therapeutic intervention. <i>Nature Reviews Clinical Oncology</i> , 2014, 11, 248-249.	27.6	12
128	The analysis of the outcomes and factors related to iliac obturator involvement in cutaneous melanoma patients after lymph node dissection due to positive sentinel lymph node biopsy or clinically detected inguinal metastases. <i>European Journal of Surgical Oncology</i> , 2013, 39, 304-310.	1.0	11
129	Completion lymph node dissection after a positive sentinel node. <i>Current Opinion in Oncology</i> , 2013, 25, 152-159.	2.4	24
130	Comments and controversies. <i>Melanoma Research</i> , 2013, 23, 181-184.	1.2	3
131	A costly revolution for a subgroup of patients with metastatic melanoma. <i>British Journal of Dermatology</i> , 2013, 168, 467-470.	1.5	3
132	Increased sampling will lead to an increase in detection, but is it clinically relevant?. <i>European Journal of Cancer</i> , 2012, 48, 2488-2489.	2.8	2
133	EORTC Melanoma Group achievements. <i>European Journal of Cancer, Supplement</i> , 2012, 10, 112-119.	2.2	0
134	Sensitivity rate of ultrasound (US)-guided fine-needle aspiration cytology (FNAC) using the Berlin morphology criteria for lymph node metastases to reduce the need for surgical sentinel node (SN) staging in melanoma. <i>Journal of Clinical Oncology</i> , 2012, 30, 8535-8535.	1.6	1
135	Genotype characterization and prognosis of unknown primary melanoma patients with nodal metastases. <i>Journal of Clinical Oncology</i> , 2012, 30, e19022-e19022.	1.6	0
136	Outcome After Therapeutic Lymph Node Dissection in Patients with Unknown Primary Melanoma Site. <i>Annals of Surgical Oncology</i> , 2011, 18, 3586-3592.	1.5	52
137	Prognosis in Patients With Sentinel Node-Positive Melanoma Is Accurately Defined by the Combined Rotterdam Tumor Load and Dewar Topography Criteria. <i>Journal of Clinical Oncology</i> , 2011, 29, 2206-2214.	1.6	195
138	Reply to I. Satzger et al. <i>Journal of Clinical Oncology</i> , 2011, 29, 3590-3591.	1.6	1
139	Reply to H. Starz et al. <i>Journal of Clinical Oncology</i> , 2011, 29, 4844-4844.	1.6	0
140	Fine Needle Aspiration Cytology of Palpable and Nonpalpable Lymph Nodes to Detect Metastatic Melanoma. <i>Journal of the National Cancer Institute</i> , 2011, 103, 1771-1777.	6.3	39
141	New developments in sentinel node staging in melanoma: controversies and alternatives. <i>Current Opinion in Oncology</i> , 2010, 22, 169-177.	2.4	48
142	Potential Cost-Effectiveness of US-Guided FNAC in Melanoma Patients as a Primary Procedure and in Follow-Up. <i>Annals of Surgical Oncology</i> , 2010, 17, 660-662.	1.5	21
143	Multimarker Reverse Transcriptase-Polymerase Chain Reaction Assay in Lymphatic Drainage and Sentinel Node Tumor Burden. <i>Annals of Surgical Oncology</i> , 2010, 17, 3314-3323.	1.5	8
144	Surgery of Primary Melanomas. <i>Cancers</i> , 2010, 2, 824-841.	3.7	16

#	ARTICLE	IF	CITATIONS
145	Epidemiology of Extracutaneous Melanoma in the Netherlands. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1453-1459.	2.5	32
146	Ultrasound Morphology Criteria Predict Metastatic Disease of the Sentinel Nodes in Patients With Melanoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 847-852.	1.6	138
147	Role of Ultrasound in the Assessment of the Sentinel Node of Melanoma Patients. <i>American Journal of Roentgenology</i> , 2010, 195, W474-W475.	2.2	4
148	Unusual first presentation of metastatic pancreatic cancer as skin metastases in a burn patient. <i>Burns</i> , 2010, 36, e111-e114.	1.9	8
149	EORTC Melanoma Group sentinel node protocol identifies high rate of submicrometastases according to Rotterdam Criteria. <i>European Journal of Cancer</i> , 2010, 46, 2414-2421.	2.8	59
150	Importance of tumor load in the sentinel node in melanoma: clinical dilemmas. <i>Nature Reviews Clinical Oncology</i> , 2010, 7, 446-454.	27.6	43
151	Rotterdam Criteria for Sentinel Node (SN) Tumor Burden and the Accuracy of Ultrasound (US) -Guided Fine-Needle Aspiration Cytology (FNAC): Can US-Guided FNAC Replace SN Staging in Patients With Melanoma?. <i>Journal of Clinical Oncology</i> , 2009, 27, 4994-5000.	1.6	102
152	Expert opinion in melanoma: The sentinel node; EORTC Melanoma Group recommendations on practical methodology of the measurement of the microanatomic location of metastases and metastatic tumour burden. <i>European Journal of Cancer</i> , 2009, 45, 2736-2742.	2.8	56
153	Detection of melanoma micrometastases in sentinel nodes – The cons. <i>Surgical Oncology</i> , 2008, 17, 175-181.	1.6	18
154	The Rotterdam Criteria for Sentinel Node Tumor Load: The Simplest Prognostic Factor?. <i>Journal of Clinical Oncology</i> , 2008, 26, 6011-6011.	1.6	9
155	Impact of Molecular Staging Methods in Primary Melanoma: Reverse-Transcriptase Polymerase Chain Reaction (RT-PCR) of Ultrasound-Guided Aspirate of the Sentinel Node Does Not Improve Diagnostic Accuracy, But RT-PCR of Peripheral Blood Does Predict Survival. <i>Journal of Clinical Oncology</i> , 2008, 26, 5742-5747.	1.6	17
156	Sentinel Node Tumor Burden According to the Rotterdam Criteria Is the Most Important Prognostic Factor for Survival in Melanoma Patients. <i>Annals of Surgery</i> , 2008, 248, 949-955.	4.2	225
157	Sentinel lymph-node false positivity in melanoma. <i>Nature Clinical Practice Oncology</i> , 2008, 5, E2-E2.	4.3	8
158	Morbidity and prognosis after therapeutic lymph node dissections for malignant melanoma. <i>European Journal of Surgical Oncology</i> , 2007, 33, 102-108.	1.0	114
159	High positive sentinel node identification rate by EORTC melanoma group protocol. <i>European Journal of Cancer</i> , 2006, 42, 372-380.	2.8	96
160	Sentinel node biopsy for clear cell sarcoma. <i>European Journal of Surgical Oncology</i> , 2006, 32, 996-999.	1.0	35
161	Isolated limb perfusion for an irresectable melanoma recurrence in a Jehovah's witness. <i>European Journal of Cardio-thoracic Surgery</i> , 2006, 30, 408-410.	1.4	3
162	Clinical relevance of melanoma micrometastases (<0.1 mm) in sentinel nodes: are these nodes to be considered negative?. <i>Annals of Oncology</i> , 2006, 17, 1578-1585.	1.2	246